Meiragtx Holdings Plc (MGTX)

2026-07-08T11:45:12.000Z - 18 days ago

MeiraGTx price target raised to $26 from $25 at RBC Capital

2026-07-07T11:40:24.000Z - 19 days ago

MeiraGTx announces $400M investment by Oberland Capital

Jul 7, 2026, 7:30 AM EDT - 19 days ago

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

Jun 11, 2026, 10:00 AM EDT - 6 weeks ago

MeiraGTx Holdings Transcript: AGM 2026

Jun 4, 2026, 3:10 PM EDT - 7 weeks ago

MeiraGTx Holdings Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 3:10 PM EDT - 7 weeks ago

MeiraGTx Holdings Slides: FY 2026

Jun 3, 2026, 7:00 AM EDT - 7 weeks ago

MeiraGTx Holdings Slides: Corporate presentation

May 14, 2026, 4:30 PM EDT - 2 months ago

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-05-14T16:16:51.000Z - 2 months ago

MeiraGTx reports Q1 EPS (57c), consensus (45c)

May 14, 2026, 8:00 AM EDT - 2 months ago

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

May 14, 2026, 8:00 AM EDT - 2 months ago

MeiraGTx Holdings Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 2 months ago

MeiraGTx Holdings Quarterly report: Q1 2026

May 13, 2026, 8:00 PM EDT - 2 months ago

MeiraGTx Holdings Transcript: Bank of America Global Healthcare Conference 2026

Apr 30, 2026, 8:00 AM EDT - 3 months ago

MeiraGTx Holdings Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

MeiraGTx Holdings Proxy statement: Proxy filing

2026-04-22T11:34:08.000Z - 3 months ago

MeiraGTx price target raised to $30 from $26 at Piper Sandler

JNJ

2026-04-17T13:19:37.000Z - 3 months ago

MeiraGTx price target raised to $24 from $16 at RBC Capital

2026-04-16T12:00:53.000Z - 3 months ago

MeiraGTx announces three-year data from Phase 1 AQUAx study

Apr 16, 2026, 8:00 AM EDT - 3 months ago

MeiraGTx Holdings Transcript: KOL event

Apr 16, 2026, 8:00 AM EDT - 3 months ago

MeiraGTx Holdings Press release: KOL event

Apr 16, 2026, 8:00 AM EDT - 3 months ago

MeiraGTx Holdings Slides: KOL event

Apr 16, 2026, 7:47 AM EDT - 3 months ago

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

2026-04-16T11:45:30.000Z - 3 months ago

MeiraGTx announces acquisition of bota-vec for treatment of XLRP

JNJ

Apr 16, 2026, 7:10 AM EDT - 3 months ago

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Apr 16, 2026, 7:00 AM EDT - 3 months ago

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

Apr 16, 2026, 6:00 AM EDT - 3 months ago

MeiraGTx Holdings Slides: Corporate presentation

Apr 14, 2026, 8:30 AM EDT - 3 months ago

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

2026-04-01T11:59:11.000Z - 4 months ago

MeiraGTx price target lowered to $18 from $20 at Evercore ISI

2026-03-27T11:01:18.000Z - 4 months ago

MeiraGTx price target lowered to $26 from $30 at Piper Sandler

2026-03-27T10:26:11.000Z - 4 months ago

MeiraGTx price target raised to $16 from $14 at BofA

Mar 26, 2026, 8:30 AM EDT - 4 months ago

MeiraGTx Holdings Annual report: Q4 2025

Mar 26, 2026, 8:30 AM EDT - 4 months ago

MeiraGTx Holdings Earnings release: Q4 2025

Mar 26, 2026, 8:00 AM EDT - 4 months ago

MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

Mar 25, 2026, 11:00 AM EDT - 4 months ago

MeiraGTx Holdings Transcript: RBC Capital Markets Virtual Ophthalmology Conference

2026-02-03T13:16:56.000Z - 6 months ago

MeiraGTx and ZipBio sign exclusive license agreement for geographic atrophy

Feb 3, 2026, 8:00 AM EST - 6 months ago

ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy

Nov 20, 2025, 3:00 PM EST - 8 months ago

Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference

Nov 13, 2025, 8:00 AM EST - 9 months ago

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

Nov 13, 2025, 8:00 AM EST - 9 months ago

MeiraGTx Holdings Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

MeiraGTx Holdings Earnings release: Q3 2025

Nov 10, 2025, 9:10 AM EST - 9 months ago

Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease

LLY

Nov 10, 2025, 7:00 AM EST - 9 months ago

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

Oct 21, 2025, 3:30 PM EDT - 9 months ago

MeiraGTx Holdings Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 7, 2025, 8:00 AM EDT - 10 months ago

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Aug 14, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

Aug 14, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Holdings Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Holdings Earnings release: Q2 2025

Jul 1, 2025, 7:00 AM EDT - 1 year ago

MeiraGTx Holdings Slides: Corporate Presentation

May 13, 2025, 4:30 PM EDT - 1 year ago

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 13, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Holdings Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Holdings Earnings release: Q1 2025

May 9, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

Apr 30, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Holdings Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Holdings Proxy statement: Proxy Filing

Apr 29, 2025, 7:11 AM EDT - 1 year ago

Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more

Apr 3, 2025, 11:30 AM EDT - 1 year ago

MeiraGTx Holdings Transcript: RBC Inaugural Virtual Ophthalmology Conference

Mar 13, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

Mar 13, 2025, 7:30 AM EDT - 1 year ago

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

Mar 12, 2025, 7:00 PM EDT - 1 year ago

MeiraGTx Holdings Earnings release: Q4 2024

Mar 12, 2025, 7:00 PM EDT - 1 year ago

MeiraGTx Holdings Annual report: Q4 2024

Feb 21, 2025, 8:00 AM EST - 1 year ago

MeiraGTx Holdings Transcript: Study Update

Feb 21, 2025, 8:00 AM EST - 1 year ago

MeiraGTx Holdings Press release: Study Update

Feb 21, 2025, 8:00 AM EST - 1 year ago

MeiraGTx Holdings Slides: Study Update

Feb 21, 2025, 6:30 AM EST - 1 year ago

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

Jan 22, 2025, 8:30 AM EST - 1 year ago

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

Nov 13, 2024, 8:30 AM EST - 1 year ago

MeiraGTx Holdings Quarterly report: Q3 2024

Oct 9, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

Sep 30, 2024, 1:00 PM EDT - 1 year ago

MeiraGTx Holdings Transcript: Chardan's 8th Annual Genetic Medicines Conference

Aug 12, 2024, 7:05 AM EDT - 2 years ago

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results

Aug 12, 2024, 7:03 AM EDT - 2 years ago

MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

Aug 12, 2024, 7:00 AM EDT - 2 years ago

MeiraGTx Holdings Quarterly report: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

MeiraGTx Holdings Earnings release: Q2 2024

Jun 12, 2024, 2:40 PM EDT - 2 years ago

MeiraGTx Holdings Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 12, 2024, 2:40 PM EDT - 2 years ago

MeiraGTx Holdings Slides: Goldman Sachs 45th Annual Global Healthcare Conference

May 15, 2024, 1:40 PM EDT - 2 years ago

MeiraGTx Holdings Transcript: BofA Securities Health Care Conference 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

May 9, 2024, 7:00 AM EDT - 2 years ago

MeiraGTx Holdings Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

MeiraGTx Holdings Earnings release: Q1 2024

Apr 29, 2024, 11:00 AM EDT - 2 years ago

MeiraGTx Holdings Transcript: Chardan's 8th Annual Genetic Medicines + Cell Therapy Manufacturing Summit (Virtual)

Apr 25, 2024, 8:00 AM EDT - 2 years ago

MeiraGTx Holdings Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

MeiraGTx Holdings Proxy statement: Proxy Filing

Apr 24, 2024, 4:30 PM EDT - 2 years ago

MeiraGTx to Participate in Upcoming Investor Conferences

Apr 18, 2024, 4:30 PM EDT - 2 years ago

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

Mar 14, 2024, 8:30 AM EDT - 2 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates

Mar 14, 2024, 7:00 AM EDT - 2 years ago

MeiraGTx Holdings Annual report: Q4 2023

Mar 14, 2024, 7:00 AM EDT - 2 years ago

MeiraGTx Holdings Earnings release: Q4 2023

Dec 21, 2023, 7:30 AM EST - 2 years ago

MeiraGTx Holdings Slides: Corporate Presentation

Dec 21, 2023, 7:00 AM EST - 2 years ago

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

Dec 21, 2023, 7:00 AM EST - 2 years ago

MeiraGTx Holdings Registration statement: Registration Filing

Nov 14, 2023, 8:00 AM EST - 2 years ago

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

Nov 14, 2023, 7:00 AM EST - 2 years ago

MeiraGTx Holdings Quarterly report: Q3 2023

Nov 14, 2023, 7:00 AM EST - 2 years ago

MeiraGTx Holdings Earnings release: Q3 2023

Oct 30, 2023, 8:28 AM EDT - 2 years ago

MeiraGTx shares jump as Sanofi invests in gene therapy

SNY

Oct 30, 2023, 7:30 AM EDT - 2 years ago

MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

Oct 24, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

Aug 10, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

Aug 10, 2023, 7:00 AM EDT - 3 years ago

MeiraGTx Holdings Quarterly report: Q2 2023

Aug 10, 2023, 7:00 AM EDT - 3 years ago

MeiraGTx Holdings Earnings release: Q2 2023

Aug 3, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Holdings Registration statement: Registration Filing

Aug 3, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Holdings Registration statement: Registration Filing

Aug 1, 2023, 9:10 AM EDT - 3 years ago

MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology

Jul 19, 2023, 8:30 AM EDT - 3 years ago

MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing

Jun 27, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Holdings Transcript: Study Update

Jun 27, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Holdings Press release: Study Update

Jun 27, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Holdings Slides: Study Update

Jun 27, 2023, 7:30 AM EDT - 3 years ago

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Jun 22, 2023, 4:01 PM EDT - 3 years ago

MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,

May 11, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Reports First Quarter 2023 Financial and Operational Results

May 11, 2023, 7:00 AM EDT - 3 years ago

MeiraGTx Holdings Quarterly report: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

MeiraGTx Holdings Earnings release: Q1 2023

May 3, 2023, 8:30 AM EDT - 3 years ago

MeiraGTx Announces $60 Million Private Placement of Ordinary Shares

Apr 27, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Holdings Proxy statement: Proxy Filing

Apr 27, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Holdings Proxy statement: Proxy Filing

Apr 21, 2023, 8:30 AM EDT - 3 years ago

MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Mar 14, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

Mar 14, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Holdings Annual report: Q4 2022

Mar 14, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Holdings Earnings release: Q4 2022

Jan 20, 2023, 7:00 AM EST - 3 years ago

MeiraGTx Holdings Proxy statement: Proxy Filing

Dec 23, 2022, 7:00 AM EST - 3 years ago

MeiraGTx Holdings Proxy statement: Proxy Filing

Dec 13, 2022, 8:00 AM EST - 3 years ago

MeiraGTx Holdings Transcript: Study Update

Dec 13, 2022, 8:00 AM EST - 3 years ago

MeiraGTx Holdings Press release: Study Update

Dec 13, 2022, 8:00 AM EST - 3 years ago

MeiraGTx Holdings Slides: Study Update

Dec 8, 2022, 4:30 PM EST - 3 years ago

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022

Nov 10, 2022, 7:00 AM EST - 4 years ago

MeiraGTx Holdings Quarterly report: Q3 2022

Nov 10, 2022, 7:00 AM EST - 4 years ago

MeiraGTx Holdings Earnings release: Q3 2022

Oct 4, 2022, 8:00 AM EDT - 4 years ago

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress

Oct 1, 2022, 10:00 AM EDT - 4 years ago

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)

Sep 16, 2022, 2:00 AM EDT - 4 years ago

MeiraGTx's Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government

Aug 11, 2022, 8:30 AM EDT - 4 years ago

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

Aug 11, 2022, 7:00 AM EDT - 4 years ago

MeiraGTx Holdings Quarterly report: Q2 2022

Aug 11, 2022, 7:00 AM EDT - 4 years ago

MeiraGTx Holdings Earnings release: Q2 2022

Aug 3, 2022, 8:00 AM EDT - 4 years ago

MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities